Neurodegenerative and ophthalmic diseases are typically propelled by the loss of specific types of neurons. For instance, Parkinson's disease is driven by the death of dopaminergic cells, while retinitis pigmentosa is propelled by the death of photoreceptors. However, under the natural state, human neural cells lack the capacity for regeneration, rendering these diseases challenging to reverse at present.

Our goal is to reverse neurological and ocular diseases through the regeneration of disease-relevant, functional, and durable neurons in vivo.

We are driven by our mission to develop regenerative medicines for patients suffering from neurological or ocular diseases.